Biomarker-aided Clinical Decision Making in CLL: Conclusions from the Workshops and Future Perspectives
Session VII of ERIC 2018 meeting provides us with a stimulating set of conclusions following the workshops on the implementation of biomarkers in the clinical environment.
Blanca Espinet, PhD, and Claudia Haferlach, MD, PhD, present conclusions on cytogenetics and Lesley Ann Sutton, PhD, discusses recurrent gene mutations.
Alessandra Tedeschi, MD, discusses clinical considerations for tailored treatment, while Davide Rossi, MD, PhD, explores the art of synthesis in the prognostication in CLL.
Presentations
Hospital del Mar Institute of Medical Research, Barcelona, Spain
Claudia Haferlach, MD
Munich Leukemia Laboratory, Munich, Germany
Blanca Espinet, PhD, from Hospital del Mar Institute of Medical Research, Barcelona, Spain, and Claudia Haferlach, MD, from Munich Leukemia Laboratory, Munich, Germany discusses conclusions on cytogenetics.
Karolinska Institute, Solna, Stockholm, Sweden
Lesley Ann Sutton, from Karolinska Institute, Solna, Stockholm, Sweden, talks about a presentation with Jitka Malčíková, PhD, Masaryk University, Brno, Czech Republic, on recurrent gene mutations.
Niguarda Cancer Center, Milan, Italy
Alessandra Tedeschi, MD, from Niguarda Cancer Center, Milan, Italy, discusses tailoring treatment: clinical considerations. Francesc Bosch, MD, PhD, from Vall d’Hebron Institute of Oncology, Barcelona, Spain and Florence Cymbalista, Avicenne Hospital, Bobigny, France, were co-authors.
Institute of Southern Switzerland, Bellinzona, Switzerland
Davide Rossi, MD, PhD, from the Institute of Southern Switzerland, Bellinzona, Switzerland, talks on Prognostication in CLL.
